
No image published for this recall
Distribution of spikevax (elasomeran) covid-19 vaccine with english-only vial and carton labels
Official notice
10 Nov 2021
Last checked
10 Nov 2021
An official Health Canada notice concerns Distribution of spikevax (elasomeran) covid-19 vaccine with english-only vial and carton labels. IMPORTANT: Access to Canadian-specific labelling information during the distribution of the SPIKEVAX (elasomeran) COVID-19 Vaccine with English-only vial and carton labels. Audience Healthcare professionals including infectious disease physicians, pharmacists, family physicians, public health officials, nurses and nurse practitioners. Healthcare professionals at the identified points of use. Key messages On December 23, 2020, COVID-19 Vaccine Moderna (DIN 02510014) was authorized in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. On September 16, 2021 COVID-19 Vaccine Moderna was issued a Notice of Compliance (NOC) under the Food and Drug Regulations and is now authorized under the brand name SPIKEVAX (elasomeran). At this time, Moderna is providing vaccine supplies with global English-only vial and carton labels, with the brand name SPIKEVAX, in order to maintain access to the vaccine in Canada (see Appendix A and Appendix B). Existing vaccine supply labelled as COVID-19 Vaccine Moderna on the vial and carton, that is within expiry, may continue to be used. To avoid excessive puncturing and compromising product integrity, DO NOT puncture and withdraw doses from the COVID-19 Vaccine Moderna / SPIKEVAX vials more than 20 times. Healthcare professionals are advised that: Important Canadian-specific information is absent from the vial and carton labels (see the Information for healthcare professionals section). The Canadian-specific labelling information including the SPIKEVAX Product Monograph and training materials can be accessed at www.modernacovid19global.com/ca, or by scanning the QR code on the English-only vial and carton labels. This information is also available on the federal government’s covid-vaccine.canada.ca website. The Canadian SPIKEVAX Product Monograph in French and English is also available on Health Canada’s Drug Product Database. Moderna will develop Canadian-specific vial and carton labels with the SPIKEVAX brand name in French and English, and make them available on the www.modernacovid19global.com/ca website at a future date. What is the issue? SPIKEVAX (elasomeran) was issued a Notice of Compliance (NOC) under the Food and Drug Regulations, replacing the previous authorization under the Interim Order. As an extraordinary measure to provide access to vaccine supplies in the context of the global pandemic, at this time Moderna is providing vaccine supplies with vials and cartons labelled with the brand name SPIKEVAX. This label is presented in English-only and is missing some important Canadian-specific information normally found on Health Canada approved labels (see the Information for healthcare professionals section). Products affected SPIKEVAX (elasomeran) (100 mcg / 0.5mL), dispersion for intramuscular injection, multidose vial (5 mL). DIN: 02510014 Manufacturer: ModernaTx, Inc. Canadian Importer and Distributor: Innomar Strategies Background information SPIKEVAX (elasomeran mRNA vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. Given the public health emergency resulting from the current pandemic, Health Canada has authorized the importation, sale, and advertising of SPIKEVAX with vial and carton labels that are in English-only for the global distribution of the vaccine. SPIKEVAX with English-only labels is the same as the Health Canada authorized COVID-19 Vaccine Moderna / SPIKEVAX in all aspects (i.e., formulation, strength, route of administration) and should be used in Canada for the same indication and per the same vaccination schedule. The Canadian SPIKEVAX Product Monograph, which is approved by Health Canada and available in French and English, should be used for complete product information. Information for healthcare professionals In order to provide rapid access to SPIKEVAX for Canadians, Moderna will provide product vials and cartons labelled in English-only for a limited time period (see Appendix A and Appendix B). Healthcare professionals are advised that: The Canadian-specific information including the SPIKEVAX Product Monograph and training materials can be accessed at www.modernacovid19global.com/ca, or by scanning the QR code on carton and vial labels. This information is also available on the federal government’s covid-vaccine.canada.ca website. The Canadian SPIKEVAX Product Monograph in French and English is also available on Health Canada’s Drug Product Database. The following important Canadian-specific information is absent from the vial and carton labels: Drug Identification Number (DIN) name and address of the Canadian DIN holder name and address of the Canadian importer and distributor all corresponding text in French To avoid excessive puncturing and compromising product integrity, DO NOT puncture and withdraw doses from the COVID-19 Vaccine Moderna / SPIKEVAX vials more than 20 times. Action taken by Health Canada Health Canada is permitting the use of global English-only vial and carton labels for SPIKEVAX for a limited period. Health Canada has imposed terms and conditions requiring Moderna to provide vaccine supplies with Canadian-specific labels as soon as possible. Health Canada has made full labelling information available in French and English on the federal government’s covid-vaccine.canada.ca website. Health Canada is communicating this important safety information to healthcare professionals and Canadians via the Recalls and Safety Alerts Database on the Healthy Canadians Web Site. This communication will be further distributed through the MedEffect™ e-Notice email notification system, as well as through social media channels, including LinkedIn and Twitter. Report health or safety concerns Managing marketed health product-related side effects depends on healthcare professionals and consumers reporting them. Any serious or unexpected side effects in patients receiving SPIKEVAX should be reported to your local Health Unit or Moderna. Moderna Biopharma Canada Corporation c/o SE Corporate Services Ltd., Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8 Telephone: 1-866-663-3762 Fax: 1-866-599-1342 To correct your mailing address or fax number, contact Moderna Biopharma Canada Corporation at 1-866-MODERNA (1-866-663-3762). If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory (https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization/form.html) and send it to your local Health Unit. For other health product inquiries related to this communication, contact Health Canada at: Biologic and Radiopharmaceutical Drugs Directorate E-mail: brdd.dgo.enquiries@hc-sc.gc.ca Original signed by Leslie Madden, BSc, MBA, LLM Director, Head of Regulatory Affairs Canada ModernaTx, Inc. Appendix A – Vial and carton labels for SPIKEVAX (elasomeran) with English-only labelling, version 1 SPIKEVAX Vial Label COVID-19 Vaccine Moderna Store frozen at -25°C to -15°C. Read the package leaflet before use. Moderna Biotech Spain SL [QR code] Scan for package leaflet or visit www.ModernaCovid19Global.com spikevax™ 0.20 mg/mL Dispersion for Injection COVID-19 mRNA Vaccine (nucleoside modified) Intramuscular Use Discard Date/Time: Multidose vial (10 doses of 0.5 mL) LOT EXP SPIKEVAX Carton Label Moderna spikevax™ 0.20 mg/mL Dispersion for Injection COVID-19 mRNA Vaccine (nucleoside modified) Intramuscular Use COVID-19 Vaccine Moderna 10 multidose vials (each vial contains 10 doses of 0.5 mL) Black box contains: PC EXP LOT Moderna™ Moderna Biotech Spain SL Calle Monte Esquinza 30, Bajo Izquierda 28010, Madrid, Spain Each multidose vial contains 10 doses (0.5 mL each). Also contains Lipid SM-102, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG), trometamol, trometamol hydrochloride, acetic acid, sodium acetate trihydrate, sucrose, water for injections. Store frozen at -25°C to -15°C. Read the package leaflet for the shelf life after first opening and for additional storage information. Keep the vial in the outer carton to protect from light. Keep out of sight and reach of children. Dispose of in accordance with local requirements. [QR code] Read the package leaflet before use. Scan here for package leaflet or visit www.ModernaCOVID-19Global.com Appendix B – Vial and carton labels for SPIKEVAX (elasomeran) with English-only labelling, version 2 SPIKEVAX Vial Label COVID-19 Vaccine Moderna Store frozen at -25°C to -15°C. Discard Date/Time: ________________ Read the package leaflet before use. Moderna Biotech Spain SL [QR code] Scan for package leaflet or visit www.ModernaCovid19Global.com spikevax™ elasomeran 0.20 mg/mL Dispersion for Injection COVID-19 mRNA Vaccine (nucleoside modified) Intramuscular Use Multidose vial (5 mL) LOT EXP SPIKEVAX Carton Label Moderna spikevax™ elasomeran 0.20 mg/mL Dispersion for Injection COVID-19 mRNA Vaccine (nucleoside modified) Intramuscular Use COVID-19 Vaccine Moderna 10 multidose vials (each vial contains 5 mL) Black box contains: PC EXP LOT Moderna™ Moderna Biotech Spain SL Calle Monte Esquinza 30, Bajo Izquierda 28010, Madrid, Spain Each multidose vial contains 5 mL. Also contains Lipid SM-102, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG), trometamol, trometamol hydrochloride, acetic acid, sodium acetate trihydrate, sucrose, water for injections. Store frozen at -25°C to -15°C. Read the package leaflet for the shelf life after first opening and for additional storage information. Keep the vial in the outer carton to protect from light. Keep out of sight and reach of children. Dispose of in accordance with local requirements. [QR code] Read the package leaflet before use. Scan here for package leaflet or visit www.ModernaCOVID-19Global.com Published 2021-11-10.
What to do now
On December 23, 2020, COVID-19 Vaccine Moderna (DIN 02510014) was authorized in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. On September 16, 2021 COVID-19 Vaccine Moderna was issued a Notice of Compliance (NOC) under the Food and Drug Regulations and is now authorized under the brand name SPIKEVAX (elasomeran).
Recall number
63576
Official notice
2021-11-10
The hazard
The hazard
IMPORTANT: Access to Canadian-specific labelling information during the distribution of the SPIKEVAX (elasomeran) COVID-19 Vaccine with English-only vial and carton labels. Audience Healthcare professionals including infectious disease physicians, pharmacists, family physicians, public health officials, nurses and nurse practitioners. Healthcare professionals at the identified points of use. Key messages On December 23, 2020, COVID-19 Vaccine Moderna (DIN 02510014) was authorized in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. On September 16, 2021 COVID-19 Vaccine Moderna was issued a Notice of Compliance (NOC) under the Food and Drug Regulations and is now authorized under the brand name SPIKEVAX (elasomeran). At this time, Moderna is providing vaccine supplies with global English-only vial and carton labels, with the brand name SPIKEVAX, in order to maintain access to the vaccine in Canada (see Appendix A and Appendix B). Existing vaccine supply labelled as COVID-19 Vaccine Moderna on the vial and carton, that is within expiry, may continue to be used. To avoid excessive puncturing and compromising product integrity, DO NOT puncture and withdraw doses from the COVID-19 Vaccine Moderna / SPIKEVAX vials more than 20 times. Healthcare professionals are advised that: Important Canadian-specific information is absent from the vial and carton labels (see the Information for healthcare professionals section). The Canadian-specific labelling information including the SPIKEVAX Product Monograph and training materials can be accessed at www.modernacovid19global.com/ca, or by scanning the QR code on the English-only vial and carton labels. This information is also available on the federal government’s covid-vaccine.canada.ca website. The Canadian SPIKEVAX Product Monograph in French and English is also available on Health Canada’s Drug Product Database. Moderna will develop Canadian-specific vial and carton labels with the SPIKEVAX brand name in French and English, and make them available on the www.modernacovid19global.com/ca website at a future date. What is the issue? SPIKEVAX (elasomeran) was issued a Notice of Compliance (NOC) under the Food and Drug Regulations, replacing the previous authorization under the Interim Order. As an extraordinary measure to provide access to vaccine supplies in the context of the global pandemic, at this time Moderna is providing vaccine supplies with vials and cartons labelled with the brand name SPIKEVAX. This label is presented in English-only and is missing some important Canadian-specific information normally found on Health Canada approved labels (see the Information for healthcare professionals section). Products affected SPIKEVAX (elasomeran) (100 mcg / 0.5mL), dispersion for intramuscular injection, multidose vial (5 mL). DIN: 02510014 Manufacturer: ModernaTx, Inc. Canadian Importer and Distributor: Innomar Strategies Background information SPIKEVAX (elasomeran mRNA vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. Given the public health emergency resulting from the current pandemic, Health Canada has authorized the importation, sale, and advertising of SPIKEVAX with vial and carton labels that are in English-only for the global distribution of the vaccine. SPIKEVAX with English-only labels is the same as the Health Canada authorized COVID-19 Vaccine Moderna / SPIKEVAX in all aspects (i.e., formulation, strength, route of administration) and should be used in Canada for the same indication and per the same vaccination schedule. The Canadian SPIKEVAX Product Monograph, which is approved by Health Canada and available in French and English, should be used for complete product information. Information for healthcare professionals In order to provide rapid access to SPIKEVAX for Canadians, Moderna will provide product vials and cartons labelled in English-only for a limited time period (see Appendix A and Appendix B). Healthcare professionals are advised that: The Canadian-specific information including the SPIKEVAX Product Monograph and training materials can be accessed at www.modernacovid19global.com/ca, or by scanning the QR code on carton and vial labels. This information is also available on the federal government’s covid-vaccine.canada.ca website. The Canadian SPIKEVAX Product Monograph in French and English is also available on Health Canada’s Drug Product Database. The following important Canadian-specific information is absent from the vial and carton labels: Drug Identification Number (DIN) name and address of the Canadian DIN holder name and address of the Canadian importer and distributor all corresponding text in French To avoid excessive puncturing and compromising product integrity, DO NOT puncture and withdraw doses from the COVID-19 Vaccine Moderna / SPIKEVAX vials more than 20 times. Action taken by Health Canada Health Canada is permitting the use of global English-only vial and carton labels for SPIKEVAX for a limited period. Health Canada has imposed terms and conditions requiring Moderna to provide vaccine supplies with Canadian-specific labels as soon as possible. Health Canada has made full labelling information available in French and English on the federal government’s covid-vaccine.canada.ca website. Health Canada is communicating this important safety information to healthcare professionals and Canadians via the Recalls and Safety Alerts Database on the Healthy Canadians Web Site. This communication will be further distributed through the MedEffect™ e-Notice email notification system, as well as through social media channels, including LinkedIn and Twitter. Report health or safety concerns Managing marketed health product-related side effects depends on healthcare professionals and consumers reporting them. Any serious or unexpected side effects in patients receiving SPIKEVAX should be reported to your local Health Unit or Moderna. Moderna Biopharma Canada Corporation c/o SE Corporate Services Ltd., Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8 Telephone: 1-866-663-3762 Fax: 1-866-599-1342 To correct your mailing address or fax number, contact Moderna Biopharma Canada Corporation at 1-866-MODERNA (1-866-663-3762). If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory (https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization/form.html) and send it to your local Health Unit. For other health product inquiries related to this communication, contact Health Canada at: Biologic and Radiopharmaceutical Drugs Directorate E-mail: brdd.dgo.enquiries@hc-sc.gc.ca Original signed by Leslie Madden, BSc, MBA, LLM Director, Head of Regulatory Affairs Canada ModernaTx, Inc. Appendix A – Vial and carton labels for SPIKEVAX (elasomeran) with English-only labelling, version 1 SPIKEVAX Vial Label COVID-19 Vaccine Moderna Store frozen at -25°C to -15°C. Read the package leaflet before use. Moderna Biotech Spain SL [QR code] Scan for package leaflet or visit www.ModernaCovid19Global.com spikevax™ 0.20 mg/mL Dispersion for Injection COVID-19 mRNA Vaccine (nucleoside modified) Intramuscular Use Discard Date/Time: Multidose vial (10 doses of 0.5 mL) LOT EXP SPIKEVAX Carton Label Moderna spikevax™ 0.20 mg/mL Dispersion for Injection COVID-19 mRNA Vaccine (nucleoside modified) Intramuscular Use COVID-19 Vaccine Moderna 10 multidose vials (each vial contains 10 doses of 0.5 mL) Black box contains: PC EXP LOT Moderna™ Moderna Biotech Spain SL Calle Monte Esquinza 30, Bajo Izquierda 28010, Madrid, Spain Each multidose vial contains 10 doses (0.5 mL each). Also contains Lipid SM-102, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG), trometamol, trometamol hydrochloride, acetic acid, sodium acetate trihydrate, sucrose, water for injections. Store frozen at -25°C to -15°C. Read the package leaflet for the shelf life after first opening and for additional storage information. Keep the vial in the outer carton to protect from light. Keep out of sight and reach of children. Dispose of in accordance with local requirements. [QR code] Read the package leaflet before use. Scan here for package leaflet or visit www.ModernaCOVID-19Global.com Appendix B – Vial and carton labels for SPIKEVAX (elasomeran) with English-only labelling, version 2 SPIKEVAX Vial Label COVID-19 Vaccine Moderna Store frozen at -25°C to -15°C. Discard Date/Time: ________________ Read the package leaflet before use. Moderna Biotech Spain SL [QR code] Scan for package leaflet or visit www.ModernaCovid19Global.com spikevax™ elasomeran 0.20 mg/mL Dispersion for Injection COVID-19 mRNA Vaccine (nucleoside modified) Intramuscular Use Multidose vial (5 mL) LOT EXP SPIKEVAX Carton Label Moderna spikevax™ elasomeran 0.20 mg/mL Dispersion for Injection COVID-19 mRNA Vaccine (nucleoside modified) Intramuscular Use COVID-19 Vaccine Moderna 10 multidose vials (each vial contains 5 mL) Black box contains: PC EXP LOT Moderna™ Moderna Biotech Spain SL Calle Monte Esquinza 30, Bajo Izquierda 28010, Madrid, Spain Each multidose vial contains 5 mL. Also contains Lipid SM-102, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG), trometamol, trometamol hydrochloride, acetic acid, sodium acetate trihydrate, sucrose, water for injections. Store frozen at -25°C to -15°C. Read the package leaflet for the shelf life after first opening and for additional storage information. Keep the vial in the outer carton to protect from light. Keep out of sight and reach of children. Dispose of in accordance with local requirements. [QR code] Read the package leaflet before use. Scan here for package leaflet or visit www.ModernaCOVID-19Global.com
How to check if you're affected
How to check if you're affected
Compare the product name and identifiers below with the item you own. Follow the official notice if they match.
Lots
Recall Numbers
Checked manually this time?
The app alerts you when a new official recall is published — no searching, no checking back.
Turn on recall alertsAffected products
Affected products
Product 1
Risk / hazard
Where it was sold
Where it was sold
The source does not list specific retailers. See the official notice for where affected products were sold.
Location 1
Affected area 1
Company & contacts
Company & contacts
Brand: Spikevax, Spikevax Covid-19 Vaccine.
Source & status
Source & status
Source
Tier
Category
App estimate
Recall details
Recall details
Recall number
Source tier
Documents, notices & source
See the official notice and source documents for full details.
View full official noticeRelated recalls

Distribution of a new presentation of spikevax (elasomeran) covid-19 vaccine (0.10 mg ml in 2.5 ml multidose vial) with english-only vial and carton labels

Shelf life extension for the spikevax (elasomeran) covid-19 vaccine with printed expiry dates on vial and carton labels

Heartsine® samaritan® pad sam 350p sam 360p sam 500p - membrane tail

Hybrid hydrophilic microguidewire

Intramedullary bone saw blade assembly

Glidesheath slender® introducer sheath

Abiomed introducer kits with impella heart pumps

Spiriva capsules ; out-of-specification (uniformity of delivered dose)

Argon medical devices l-cath™ picc and midline catheters
Image: Health Canada recall noticeImportation of chinese-authorized ifosfamide for injection due to the current shortage of canadian-authorized ifex (ifosfamide for injection)

Cyberknife® treatment delivery system

Penumbra system red 68 reperfusion catheter
Weekly recall digest
Get next week's recalls before you need them.
One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.
The digest is the slow lane — one email a week. For instant, severity-gated alerts the moment a notice is published, get the app.
This recall was published 10 Nov 2021. The next one won't wait for you to search.
RecallScope watches official sources for the brands and VINs you follow, and alerts you the moment a new notice is published.